Tirzepatide vs Retatrutide: Approved Dual Agonist vs Triple Agonist Pipeline

Tirzepatide and retatrutide are both Eli Lilly incretin drugs, but they are not in the same practical category yet.

Tirzepatide is approved and sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. Retatrutide is a next-generation triple agonist in clinical development. It has impressive trial signals, but it is not an approved prescription product.

If you want a wider pipeline map, read retatrutide and peptides for weight loss.

Quick Comparison

Question	Tirzepatide	Retatrutide
Mechanism	Dual GIP / GLP-1 receptor agonist	Triple GIP / GLP-1 / glucagon receptor agonist
Brand status	Zepbound and Mounjaro are approved medicines	No approved brand product yet
Weight-loss evidence	Large Phase 3 obesity trials and real-world prescription use	Strong Phase 2 and Phase 3 topline signals, but still pipeline
Practical answer today	The current approved option	A drug to watch, not a consumer option
Key risk	Known label risks and GI tolerability issues	Unknown long-term commercial label until review is complete

Mechanism Difference

Tirzepatide activates two receptor pathways:

• GIP.
• GLP-1.

Retatrutide activates three:

• GIP.
• GLP-1.
• Glucagon.

The glucagon arm is the major difference. In the right multi-agonist design, glucagon receptor activation may increase energy expenditure and liver fat oxidation while GLP-1 and GIP help control appetite and glucose response.

That extra receptor target may be part of why retatrutide looks powerful in trials. It may also create side-effect signals that need a full approval review and longer follow-up.

Weight Loss Data

Evidence point	Tirzepatide	Retatrutide	Interpretation
Pivotal obesity signal	SURMOUNT-1 reported up to about 20.9% average weight loss at 72 weeks	Phase 2 obesity data reported about 24% average loss at 48 weeks at the highest dose	Retatrutide looks stronger, but this is not a clean label-to-label comparison.
Direct head-to-head	Approved comparator in ongoing/pipeline comparisons	Dedicated head-to-head evidence is still developing	Do not treat cross-trial comparisons as final.
Regulatory status	FDA-approved as Zepbound for weight management	Investigational	This is the biggest practical difference.

Approval Status Matters More Than Hype

Tirzepatide can be prescribed as an approved medicine when a clinician decides it is appropriate. Its product label defines indications, dosing, warnings, contraindications and storage.

Retatrutide does not have that consumer label yet. Any site selling "retatrutide" directly to consumers is not selling an FDA-approved retatrutide medicine. That creates quality, identity, sterility, dosing and legal risk.

Side Effects

Both drugs sit in the incretin family, so nausea, vomiting, diarrhea, constipation and reduced appetite matter. Retatrutide trials have also reported signals that may relate to its broader receptor activity, including altered sensation symptoms in some reports.

For now, tirzepatide has the clearer commercial safety label. Retatrutide's final risk-benefit profile will depend on Phase 3 data, labeling and regulator review.

Which One Should People Watch?

Scenario	Practical answer	Why
Needs an approved obesity medicine now	Tirzepatide, semaglutide or another approved option	Retatrutide is not approved.
Researching next-generation drugs	Retatrutide is one of the top pipeline names	Its triple-agonist mechanism and trial data are meaningful.
Comparing online research vials	Do not equate them with clinical retatrutide	Identity, purity, sterility and dose are not guaranteed by the name on a label.
Already on tirzepatide and curious about switching later	Wait for approved labeling and clinician guidance	Future dose conversion will not be a simple mg-to-mg swap.

Bottom Line

Tirzepatide is the current practical winner because it is approved and has large Phase 3 obesity data. Retatrutide may become the stronger next-generation drug if its Phase 3 program and regulatory review hold up, but it is still a pipeline medicine.

For current approved comparisons, read semaglutide vs tirzepatide and Zepbound vs Wegovy.

FAQ

Is retatrutide better than tirzepatide?

Retatrutide has produced very large weight-loss results in trials, but it is not FDA approved and direct published head-to-head evidence against tirzepatide is still limited.

Can you buy retatrutide now?

Retatrutide is investigational. Products sold online as retatrutide are not the same as an FDA-approved prescription medicine.

What is the main difference between tirzepatide and retatrutide?

Tirzepatide activates GIP and GLP-1 receptors. Retatrutide activates GIP, GLP-1 and glucagon receptors.

Which one is approved for weight loss?

Tirzepatide is approved for chronic weight management as Zepbound. Retatrutide remains investigational.

Should someone wait for retatrutide?

That is a clinician-level decision. Someone with a medical indication today should not ignore approved options while waiting for an investigational drug.

References

1. Eli Lilly. Zepbound prescribing information.

2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine.

3. Jastreboff AM, et al. Retatrutide for obesity: a phase 2 trial. New England Journal of Medicine.

4. Eli Lilly. Retatrutide Phase 3 topline announcement.